Holen Sie sich die Stockscreener-App
13.68
1.51%
-0.215
Schlusskurs vom Vortag:
$13.89
Offen:
$13.88
24-Stunden-Volumen:
261.34K
Relative Volume:
0.46
Marktkapitalisierung:
$693.20M
Einnahmen:
$80.33M
Nettoeinkommen (Verlust:
$29.34M
KGV:
24.31
EPS:
0.5625
Netto-Cashflow:
$243.48M
1W Leistung:
+0.81%
1M Leistung:
-29.95%
6M Leistung:
-4.34%
1J Leistung:
+47.41%
1-Tages-Spanne:
$13.49
$14.06
1-Wochen-Bereich:
$13.29
$14.18
52-Wochen-Spanne:
$7.90
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Firmenname
Theravance Biopharma Inc
Sektor
Branche
Telefon
650-808-6000
Adresse
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
13.68 | 703.84M | 80.33M | 29.34M | 243.48M | 0.5625 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.55 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.20 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.63 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.89 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-03-04 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2025-12-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-12 | Eingeleitet | B. Riley Securities | Buy |
| 2024-08-06 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Eingeleitet | BTIG Research | Buy |
| 2024-01-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-10-14 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Eingeleitet | JP Morgan | Overweight |
| 2020-06-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Eingeleitet | Cowen | Outperform |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-06 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-29 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-12-21 | Eingeleitet | Needham | Buy |
| 2016-11-03 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-10-12 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Eingeleitet | Guggenheim | Buy |
| 2016-06-20 | Bestätigt | Leerink Partners | Outperform |
| 2016-05-12 | Eingeleitet | Leerink Partners | Outperform |
| 2016-05-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
Alle ansehen
Theravance Biopharma Inc Aktie (TBPH) Neueste Nachrichten
WINTON GROUP Ltd Takes $1.12 Million Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Aug Fed Impact: Can Theravance Biopharma Inc sustain its profitabilityQuarterly Market Review & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Once with 360 employees, Theravance Biopharma's latest cuts to whittle workforce to fewer than 50 - The Business Journals
How The Theravance Biopharma (TBPH) Story Is Reset Around Respiratory Assets And Cash - Yahoo Finance
Responsive Playbooks and the TBPH Inflection - Stock Traders Daily
TBPH ALERT: Levi & Korsinsky Investigates Theravance Biopharma, Inc. for Possible Securities Fraud Violations - TMX Newsfile
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) - Finviz
Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure - Markets Mojo
Portfolio Recap: Is Theravance Biopharma Inc stock showing strong momentum2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH) - Finviz
HC Wainwright Issues Optimistic Forecast for TBPH Earnings - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Theravance Biopharma winds down Ampreloxetine programme after Phase 3 miss - Indian Pharma Post
Oppenheimer Downgrades Theravance Biopharma (TBPH) to Perform, March 05 2026 - Meyka
Theravance Biopharma (TBPH) Downgraded by Oppenheimer to Perform - GuruFocus
Theravance Biopharma (NASDAQ:TBPH) Downgraded to "Market Perform" Rating by Oppenheimer - MarketBeat
Oppenheimer downgrades Theravance Biopharma stock rating on Phase 3 miss - Investing.com Australia
Theravance Biopharma Faces Weak Start with 24.7% Gap Down Amid Market Concerns - Markets Mojo
Theravance Biopharma downgraded at Oppenheimer after ampreloxetine miss - TipRanks
Theravance Biopharma Experiences Valuation Adjustment Amidst Market Dynamics and Performance Metrics - Markets Mojo
Market Moves: What’s the RSI of Theravance Biopharma Inc. stockLayoff News & Technical Buy Zone Confirmations - baoquankhu1.vn
B.Riley cuts Theravance Biopharma stock rating on trial failure - Investing.com Australia
B.Riley cuts Theravance Biopharma stock rating on trial failure By Investing.com - Investing.com Canada
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study - Yahoo Finance
Share tumbles and jobs to go after Theravance failure - The Pharmaletter
B. Riley Financial Reiterates "Neutral" Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
B. Riley Downgrades Theravance Biopharma to Neutral From Buy, Adjusts Price Target to $14 From $28 - marketscreener.com
Breaking Down Theravance Biopharma: 5 Analysts Share Their Views - Benzinga
This Vulcan Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
TBPH Analyst: HC Wainwright & Co. Lowers Price Target to $15 | T - GuruFocus
Theravance Biopharma (TBPH) Downgraded by B. Riley Securities to Neutral | TBPH Stock News - GuruFocus
Theravance to cut costs 60% after drug trial fails primary endpoint - Investing.com Canada
BTIG Maintains Buy on Theravance Biopharma, Inc. (TBPH) March 2026 - Meyka
Theravance Biopharma (TBPH): BTIG Lowers Price Target to $21.00 - GuruFocus
Theravance Biopharma Target of Unusually High Options Trading (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (TBPH) Phase 3 Study Misses Expectations - GuruFocus
Theravance Biopharma, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Resilience - Markets Mojo
Top Midday Decliners - marketscreener.com
Theravance Biopharma Plummets As Phase 3 Study Falls Short - Benzinga
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down on Analyst Downgrade - MarketBeat
BTIG cuts Theravance Biopharma stock price target on trial miss By Investing.com - Investing.com Canada
BTIG cuts Theravance Biopharma stock price target on trial miss - Investing.com
BTIG Research Lowers Theravance Biopharma (NASDAQ:TBPH) Price Target to $21.00 - MarketBeat
Theravance slashes R&D as hypotension asset fails again - BioWorld MedTech
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review - Yahoo Finance UK
Theravance Biopharma stock tumbles after trial failure - Investing.com
Theravance Biopharma stock tumbles after trial failure By Investing.com - Investing.com Australia
Theravance considers possible sale after drug trial setback - marketscreener.com
Theravance Biopharma (TBPH) Shuts Down Ampreloxetine Program Pos - GuruFocus
Theravance Biopharma's blood pressure drug fails to meet main goal in late-stage trial - marketscreener.com
Theravance Biopharma reports Phase 3 Cypress study did not meet primary endpoint; board accelerates strategic review and announces cost reduction actions - marketscreener.com
Finanzdaten der Theravance Biopharma Inc-Aktie (TBPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):